I. Toledano

419 total citations
16 papers, 287 citations indexed

About

I. Toledano is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, I. Toledano has authored 16 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in I. Toledano's work include Advanced Radiotherapy Techniques (4 papers), Head and Neck Cancer Studies (4 papers) and Radiation Dose and Imaging (3 papers). I. Toledano is often cited by papers focused on Advanced Radiotherapy Techniques (4 papers), Head and Neck Cancer Studies (4 papers) and Radiation Dose and Imaging (3 papers). I. Toledano collaborates with scholars based in France, Spain and United States. I. Toledano's co-authors include M. Lapeyre, Pierre Boisselier, S. Racadot, René‐Jean Bensadoun, Philippe Giraud, Cécile Ortholan, M. Alfonsi, P. Gräff, P. Pommier and V. Favrel and has published in prestigious journals such as International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology and Radiotherapy and Oncology.

In The Last Decade

I. Toledano

15 papers receiving 285 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Toledano France 6 143 127 95 87 77 16 287
Tosol Yu South Korea 9 99 0.7× 68 0.5× 67 0.7× 71 0.8× 137 1.8× 21 326
Giuseppe Giovinazzo Italy 9 97 0.7× 75 0.6× 130 1.4× 32 0.4× 94 1.2× 14 330
Issa Mohamad Jordan 8 78 0.5× 52 0.4× 41 0.4× 29 0.3× 66 0.9× 45 243
Pervin Hürmüz Türkiye 12 239 1.7× 47 0.4× 89 0.9× 28 0.3× 61 0.8× 55 381
Ang Qu China 12 156 1.1× 69 0.5× 195 2.1× 47 0.5× 76 1.0× 43 406
Anne Moxhon Belgium 6 186 1.3× 76 0.6× 49 0.5× 102 1.2× 134 1.7× 8 325
To Wai Leung China 9 182 1.3× 357 2.8× 260 2.7× 53 0.6× 188 2.4× 13 494
Weijun Ding China 9 152 1.1× 207 1.6× 87 0.9× 48 0.6× 66 0.9× 15 365
Douglas Klotch United States 10 85 0.6× 149 1.2× 155 1.6× 47 0.5× 133 1.7× 17 328
Jun Dang China 15 344 2.4× 33 0.3× 73 0.8× 42 0.5× 220 2.9× 43 497

Countries citing papers authored by I. Toledano

Since Specialization
Citations

This map shows the geographic impact of I. Toledano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Toledano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Toledano more than expected).

Fields of papers citing papers by I. Toledano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Toledano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Toledano. The network helps show where I. Toledano may publish in the future.

Co-authorship network of co-authors of I. Toledano

This figure shows the co-authorship network connecting the top 25 collaborators of I. Toledano. A scholar is included among the top collaborators of I. Toledano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Toledano. I. Toledano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Filippi, Andrea Riccardo, M.R. García-Campelo, Diego Cortinovis, et al.. (2024). LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial. Annals of Oncology. 35. S1241–S1241. 1 indexed citations
2.
Filippi, Andrea Riccardo, M.R. García Campelo, Diane Kowalski, et al.. (2024). 66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study. Immuno-Oncology Technology. 24. 100809–100809. 1 indexed citations
3.
García-Campelo, M.R., Diane Kowalski, Diego Cortinovis, et al.. (2023). LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study. Annals of Oncology. 34. S1302–S1302. 5 indexed citations
4.
Martínez‐Trufero, Javier, Beatriz Cirauqui, Jordi Rubió‐Casadevall, et al.. (2021). Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. Clinical & Translational Oncology. 23(8). 1666–1677. 6 indexed citations
5.
Rugo, Hope S., Fabrice André, Toshinari Yamashita, et al.. (2020). Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of Oncology. 31(8). 1001–1010. 113 indexed citations
6.
7.
8.
Biau, J., et al.. (2013). Délégation partielle du contrôle de position du patient par imagerie embarquée aux manipulateurs en électroradiologie. Cancer/Radiothérapie. 17(1). 34–38. 9 indexed citations
9.
Toledano, I., P. Gräff, Pierre Boisselier, et al.. (2012). Intensity-modulated radiotherapy in head and neck cancer: Results of the prospective study GORTEC 2004–03. Radiotherapy and Oncology. 103(1). 57–62. 102 indexed citations
10.
Toledano, I., et al.. (2012). EP-1244 RADIOBIOLOGICAL FACTORS FOR RECURRENCE IN PROPHYLACTIC RADIOTHERAPY FOR KELOIDS. DESCRIPTIVE STUDY. Radiotherapy and Oncology. 103. S476–S476. 1 indexed citations
11.
12.
13.
14.
Chargari, Cyrus, I. Toledano, Alexia Savignoni, et al.. (2010). No Evidence of Increased Skin Toxicity with Aromatase Inhibitors and Concurrent Hypofractionated Radiation Therapy in Menopausal Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 78(3). S253–S253. 1 indexed citations
15.
Gilliot, O., Xavier Durando, Catherine Abrial, et al.. (2009). Does Regional Lymph Node Irradiation Improve the Outcome of N0 and pN0 Breast Cancer?. Cancer Investigation. 28(2). 195–200. 4 indexed citations
16.
Gilliot, O., Xavier Durando, Catherine Abrial, et al.. (2009). Does Regional Lymph Node Irradiation Improve the Outcome of N0 and pN0 Breast Cancer?. Cancer Investigation. 1–1.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tosol Yu Breakdown of academic impact, for papers by Giuseppe Giovinazzo Breakdown of academic impact, for papers by Issa Mohamad Breakdown of academic impact, for papers by Pervin Hürmüz Breakdown of academic impact, for papers by Ang Qu Breakdown of academic impact, for papers by Anne Moxhon Breakdown of academic impact, for papers by To Wai Leung Breakdown of academic impact, for papers by Weijun Ding Breakdown of academic impact, for papers by Douglas Klotch Breakdown of academic impact, for papers by Jun Dang
Rankless by CCL
2026